ELVN
Enliven Therapeutics Inc.
$42.65
-$0.51(-1.18%)
71
Overall
60
Value
83
Tech
--
Quality
Market Cap
$1.12B
Volume
928.61K
52W Range
$13.30 - $40.62
Target Price
$43.88
Company Overview
| Mkt Cap | $1.12B | Price | $42.65 |
| Volume | 928.61K | Change | -1.18% |
| P/E Ratio | -12.6 | Open | $44.13 |
| Revenue | -- | Prev Close | $43.16 |
| Net Income | $-89.0M | 52W Range | $13.30 - $40.62 |
| Div Yield | N/A | Target | $43.88 |
| Overall | 71 | Value | 60 |
| Quality | -- | Technical | 83 |
No chart data available
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Latest News
JonesTrading Keeps Their Buy Rating on Enliven Therapeutics (ELVN)
TipRanks Auto-Generated Intelligence Newsdesk•2 days ago
LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)
TipRanks Auto-Generated Intelligence Newsdesk•11 days ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioAge Labs, Inc. (BIOA) and Enliven Therapeutics (ELVN)
Brian Anderson•15 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ELVN | $42.65 | -1.2% | 928.61K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enliven Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW